Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers
Authors:
Open Access
- 5 July 2024
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 73 (9) , 1-11
Abstract
Background: The long-term survival benefit of immune checkpoint inhibitors (ICIs) in neoadjuvant and adjuvant settings is unclear for colorectal cancers (CRC) and gastric cancers (GC) with deficiency of mismatch repair (dMMR) or microsatellite instability-high (MSI-H). Methods: This retrospective study enrolled patients with dMMR/MSI-H CRC and GC who received at least one dose of neoadjuvant ICIs (neoadjuvant cohort, NAC) or adjuvant ICIs (adjuvant cohort, AC) at 17 centers in China. Patients with stage IV disease were also eligible if all tumor lesions were radically resectable. Results: In NAC (n = 124), objective response rates were 75.7% and 55.4%, respectively, in CRC and GC, and pathological complete response rates were 73.4% and 47.7%, respectively. The 3-year disease-free survival (DFS) and overall survival (OS) rates were 96% (95%CI 90–100%) and 100% for CRC (median follow-up [mFU] 29.4 months), respectively, and were 84% (72–96%) and 93% (85–100%) for GC (mFU 33.0 months), respectively. In AC (n = 48), the 3-year DFS and OS rates were 94% (84–100%) and 100% for CRC (mFU 35.5 months), respectively, and were 92% (82–100%) and 96% (88–100%) for GC (mFU 40.4 months), respectively. Among the seven patients with distant relapse, four received dual blockade of PD1 and CTLA4 combined with or without chemo- and targeted drugs, with three partial response and one progressive disease. Conclusion: With a relatively long follow-up, this study demonstrated that neoadjuvant and adjuvant ICIs might be both associated with promising DFS and OS in dMMR/MSI-H CRC and GC, which should be confirmed in further randomized clinical trials.Keywords
Funding Information
- Natural Science Foundation of Beijing Municipality (No. 7232018)
- Beijing Xisike Clinical Oncology Research Foundation (Y-HH202101-0068, Y-tongshu2021/ms-0040, Y-XD202001/zb-0008)
- Clinical Research Fund For Distinguished Young Scholars of Peking University Cancer Hospital (QNJJ2022026)
- National Natural Science Foundation of China (General Program, no. 82272764)
This publication has 30 references indexed in Scilit:
- SO-19 The outcome of resected stage II colon cancer patients with deficient mismatch repair T4 tumors: A National Cancer Database analysisAnnals of Oncology, 2023
- Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatmentEuropean Journal of Cancer, 2022
- Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142Annals of Oncology, 2022
- Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 studyThe Lancet Oncology, 2022
- Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trialThe Lancet Gastroenterology & Hepatology, 2022
- Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical TrialsJAMA Oncology, 2021
- Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case seriesEuropean Journal of Surgical Oncology, 2020
- Relationship between MLH1, PMS2, MSH2 and MSH6 gene‐specific alterations and tumor mutational burden in 1057 microsatellite instability‐high solid tumorsInternational Journal of Cancer, 2020
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyThe Lancet Oncology, 2017
- Mismatch Repair Deficiency, Microsatellite Instability, and SurvivalJAMA Oncology, 2017